Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04954833 · ClinicalTrials.gov registry record
Evaluating Visual Acuity and Initial Fit Performance of Two Soft Contact Lenses
A clinical trial, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- 60
- Enrollment target
NCT04954833: Completed study, sponsored by Johnson & Johnson Vision Care.
NCT04954833 is a clinical trial that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04954833 has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, controlled, double-masked, 2x2 cross-over, non-dispensing study to compare visual acuity and lens fit performance.
Primary Outcome
Visual acuity on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by- letter results calculated the visual performance score for each chart read. LogMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.00 is equivalent to Snellen visual acuity of 20/20.
Interventions
- DEVICE EMO-200
- DEVICE EMO-118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2021-08-16 |
What the finished NCT04954833 record still lists
NCT04954833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which EMO-200 is the first listed.
NCT04954833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04954833 about?
NCT04954833 is a clinical study titled "Evaluating Visual Acuity and Initial Fit Performance of Two Soft Contact Lenses". This is a multi-center, randomized, controlled, double-masked, 2x2 cross-over, non-dispensing study to compare visual acuity and lens fit performance.
What is the current status of trial NCT04954833?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2021-06-14. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT04954833?
The interventions under investigation include: EMO-200 (DEVICE), EMO-118 (DEVICE).
Who is sponsoring clinical trial NCT04954833?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI